Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2558

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 6
Chunk 2558
---
) 
     - 
  
    Non-cash interest expense 
     -  
     -  
     35,655 
  
    Gain on revaluation of earnout and derivative liabilities 
     (4,880,000) 
     (320,117) 
     (290,264)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (87,088) 
     142,687  
     (112,321)
  
    Accounts payable 
     130,032  
     128,429  
     1,280,560 
  
    Accrued liabilities 
     2,342,593  
     (50,370) 
     44,239 
  
    Operating lease liability 
     (647,503) 
     (121,589) 
     (672,373)
  
    Net cash used in operating activities 
     (12,278,569) 
     (637,400) 
     (5,789,987)

    Cash flows from financing activities: 

    Proceeds from issuance of convertible notes 
     -  
     -  
     605,230 
  
    Issuance costs for convertible notes 
     -  
     -  
     (41,193)
  
    Common stock subscription deposit 
     -  
     -  
     1,875 
  
    Cash proceeds from exercise of common stock options 
     -  
     -  
     5,766 
  
    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     6,757,700  
     -  
     - 
  
    Advances from shareholder 
     13,731  
     -  
     - 
  
    Payment of sponsor loans 
     (19,715) 
     -  

    Payments for short term borrowings 
     (402,514) 
     -  

    Proceeds from short-term borrowings, net 
     408,052  
     -  
     - 
  
    Proceeds from share purchases under ELOC, net of issuance costs 
     4,809,703  
     -  
     - 
  
    Proceeds received from sale of Series B Preferred